Cargando…
Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
AIMS: Sodium‐glucose cotransporter 2 (SGLT2) inhibitors have been shown to be an effective therapy in improving heart failure outcomes. We conducted a meta‐analysis of randomized controlled trials to evaluate the efficacy of SGLT2 inhibitors in heart failure patients with either a reduced or preserv...
Autores principales: | Pandey, Arjun K., Dhingra, Nitish K., Hibino, Makoto, Gupta, Vijay, Verma, Subodh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934917/ https://www.ncbi.nlm.nih.gov/pubmed/35112512 http://dx.doi.org/10.1002/ehf2.13805 |
Ejemplares similares
-
The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
por: Brust-Sisti, Lindsay, et al.
Publicado: (2022) -
Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
por: Deschaine, Brent, et al.
Publicado: (2022) -
Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2021) -
Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
por: Cavka, Luka, et al.
Publicado: (2021) -
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
por: Ueda, Tomoya, et al.
Publicado: (2021)